What is the target of adagrasib?

Adagrasib (Adagrasib) targets the KRAS G12C mutant protein. KRAS is an important cell signaling regulatory protein, and its mutations are found in a variety of cancers, especially non-small cell lung cancer and colorectal cancer. Among them, KRAS G12C mutation is the most prominent type. This mutation makes the KRAS protein abnormally active, thereby promoting the proliferation, survival and metastasis of tumor cells. As a highly specific KRAS G12C inhibitor, adagrasib can precisely bind and inhibit the activity of this mutant protein. By interfering with the signaling pathway of the KRAS G12C mutant protein, adagrasib effectively blocks the growth and spread of tumor cells, thereby achieving the purpose of treating cancer.